Results 31 to 40 of about 291,520 (258)
Classifying discoid lupus erythematosus: background, gaps, and difficulties
To inform our ongoing efforts to develop defining features to be incorporated into a novel set of classification criteria for discoid lupus erythematosus (DLE), we conducted a literature review using the Ovid MEDLINE database.
Jessica S. Haber, BA +2 more
doaj +1 more source
Pathophysiology of cutaneous lupus erythematosus [PDF]
AbstractThe pathophysiology of cutaneous lupus erythematosus (CLE) encompasses the complex interactions between genetics, the environment, and cells and their products. Recent data have provided enhanced understanding of these interactions and the mechanism by which they cause disease. A number of candidate genes have been identified which increase the
Achtman, Jordan C, Werth, Victoria P
openaire +2 more sources
Capecitabine is a fluoropyrimidine chemotherapy prodrug of 5-fluorouracil (5-FU) used in the treatment of metastatic breast and colorectal cancers.
Darwin, Evan +5 more
core +1 more source
Taxane associated subacute cutaneous lupus erythematosus [PDF]
Numerous medications have been associated with the development of subacute cutaneous lupus erythematosus. A mechanism explaining how unrelated drug classes can lead to subacute cutaneous lupus erythematosus has remained elusive, suggesting that there may
Marchetti, Michael A. +8 more
core +1 more source
Subacute Cutaneous Lupus Erythematosus
Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus. These patients were noted to have prominent photoaggravated skin disease and often had musculoskeletal complaints, but generally did not develop significant systemic disease.
openaire +2 more sources
Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature [PDF]
Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE).
Morris, SD +3 more
core
Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) [PDF]
Background To assess the impact of disease activity on health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). Methods Cross-sectional study of patients included in the Swiss SLE Cohort Study between April 2007 and June 2014.
Eric Dayer +38 more
core +2 more sources
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment
Cutaneous lupus erythematosus is a previously undiagnosed side-effect of ranibizumab. Here, we present a case of an 82-year-old female Caucasian patient with wet age-related macular degeneration.
Marko Andric +4 more
doaj +1 more source
ABSTRACT Autoinflammatory disorders (AIDs) are a clinically heterogeneous group of inborn errors of immunity primarily caused by dysregulation in the innate immune system. Clinical diagnosis is often challenging due to clinical heterogeneity and the overlapping phenotypes with other inborn errors of immunity and monogenic conditions that mimic AIDs ...
Vaishnavi Ashok Badiger +28 more
wiley +1 more source

